Sequana Medical NV
Brussels Stock Exchange SEQUA.BR
Sequana Medical NV Free Cash Flow Yield on January 14, 2025: -23.54%
-
Sequana Medical NV 52-week high Free Cash Flow Yield is -16.16% on December 30, 2024, which is 31.32% above the current Free Cash Flow Yield.
-
Sequana Medical NV 52-week low Free Cash Flow Yield is -102.29% on December 19, 2024, which is -334.58% below the current Free Cash Flow Yield.
-
Sequana Medical NV average Free Cash Flow Yield for the last 52 weeks is -38.28%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Ian Crosbie |
| IPO Date | Feb. 11, 2019 |
| Location | Belgium |
| Headquarters | Kortrijksesteenweg 1112 |
| Employees | 62 |
| Sector | Health Care |
| Industries | |
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Past 5 years
USD 673.61
StockViz Staff
January 15, 2025
Any question? Send us an email